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Abstract
Background: Complementary and alternative medicine (CAM) is increasingly used for treatment of inflammatory 
bowel disease (IBD). Acupuncture-type treatments are among the most popular options. Several studies have reported 
that moxibustion is effective in ulcerative colitis (UC). The objective of this review was to assess the clinical evidence for 
or against moxibustion as a treatment for UC.
Methods: We searched the literature using 18 databases from their inception to February 10, 2010, without language 
restrictions. We included randomized clinical trials (RCTs), in which human patients with UC were treated with 
moxibustion. Studies were included if they were placebo-controlled or controlled against a drug therapy or no 
treatment group. The methodological quality of all RCTs was assessed using the Cochrane risk of bias.
Results: In total, five RCTs were included. All were of low methodological quality. They compared the effects of 
moxibustion with conventional drug therapy. Three tested moxibustion against sulfasalazine and two against 
sulfasalazine plus other drugs. A meta-analysis of five RCTs showed favorable effects of moxibustion on the response 
rate compared to conventional drug therapy (n = 407; risk ratio = 1.24, 95% CI = 1.11 to 1.38; P < 0.0001; heterogeneity: 
I2 = 16%).
Conclusions: Current evidence is insufficient to show that moxibustion is an effective treatment of UC. Most of 
included trials had high risk of bias. More rigorous studies seem warranted.
Background
Ulcerative colitis (UC) is a common, chronic idiopathic
inflammatory bowel disease (IBD) [1]. Patients typically
present with bloody diarrhea, passage of pus, mucus, or
both, and abdominal cramping during bowel movements
[2]. UC often requires lifelong medication, but poor
adherence to medication has been an important barrier
to successful management. Relapse rates are high, and the
risk of colorectal cancer has increased [3,4].
Complementary and alternative medicine (CAM) is
increasingly used for treatment of IBD [5], and acupunc-
ture and moxibustion are particularly popular options.
Moxibustion is a traditional Oriental medicine that uses
the heat generated by burning herbal preparations con-
taining  Artemisia vulgaris to stimulate acupuncture
points. Direct moxibustion is applied directly to the skin
surface at an area around an acupuncture point, whereas
indirect moxibustion is performed with some insulating
materials (e.g., ginger, salts) placed between the moxa
cone and the skin [6]. The heat is then used to warm the
skin at the acupuncture point. Several observational stud-
ies have reported that moxibustion is effective in UC [7-
9], and animal studies have suggested beneficial effects
[10,11].
A recent systematic review included clinical trials of
acupuncture for gastrointestinal disorders, showing posi-
tive effects of acupuncture [12]. Considering that moxi-
bustion is closely related to acupuncture, it seems
pertinent to evaluate the effectiveness of this therapy
under these conditions. Currently, no systematic review
of moxibustion for UC is available. Hence, it was the aim
of this systematic review to summarize and critically
evaluate the evidence for or against the effectiveness of
moxibustion as a symptomatic treatment for UC.
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Methods
Data sources
The following databases were searched from their incep-
tion through February 10, 2010 (first searched in July
2009): MEDLINE, AMED, EMBASE, CINHAL, PsycInfo,
five Korean Medical Databases (Korean Studies Informa-
tion, DBPIA, Korea Institute of Science and Technology
Information, KoreaMed, and Research Information Cen-
tre for Health Database), four Chinese Medical Databases
(China Academic Journal, Century Journal Project, China
Doctor/Master Dissertation Full Text Database, and
China Proceedings Conference Full Text Database), The
Cochrane Library 2010, Issue 1, and three Japanese elec-
tronic databases. The search terms used were "moxibus-
tion" or "ulcerative" in Korean, Chinese, or English.
Reference lists of all obtained papers were searched. We
also performed electronic searches of relevant journals
(FACT [Focus on Alternative and Complementary Ther-
apies] and Research in Complementary Medicine
[Forschende Komplementarmedizin] up to Februrary
2010). Additionally, reference lists of all obtained papers
were searched, and our own personal files were manually
searched as well. Hardcopies of all potentially relevant
articles were obtained and read in full. In addition, the
proceedings of United European Gastroenterology Week
(UEGW) from 2006 to 2009 and Digestive Disease Week
(DDW) from 2008 and 2009 were searched for other rele-
vant articles.
Study selection
We included RCTs in which human patients with UC
were treated with moxibustion. The studies were
i n c l u d e d  i f  t h e y  w e r e  p l a c e b o - c o n t r o l l e d  o r  c o n t r o l l e d
against a conventional treatment, including drug therapy
and another active treatment, or against no treatment.
Trials testing the effectiveness of moxibustion combined
with other therapies were excluded. Dissertations and
abstracts were included when they contained sufficient
details.
Data extraction, quality, and validity assessment
All articles were read by two independent reviewers
(DHL, JIK), who extracted data from the articles accord-
i n g  t o  p r e d e f i n e d  c r i t e r i a  ( T a b l e  1 ) .  R i s k  o f  b i a s  w a s
assessed using the Cochrane classification in four criteria:
sequence generation, incomplete outcome measures,
blinding, and allocation concealment [13]. Considering
that it is virtually impossible to blind therapists to the use
of moxibustion, we assessed patient and assessor blinding
separately. Disagreements were resolved by discussion
between the two reviewers (DHL, JIK), with the opinion
of a third reviewer (MSL) being sought if necessary.
There was no disagreement between the two reviewers
about the risk of bias.
Outcome measures and data synthesis
All clinical endpoints were considered, but the main out-
come measure was the response rate for treating symp-
t o m s  i n  p a t i e n t s  w i t h  U C .  W e  d i d  n o t  e v a l u a t e  t h e
outcomes related to immunological or other surrogate
endpoints. The differences between the intervention and
control groups were assessed. Relative risk (RR) and 95%
confidence intervals (CIs) were calculated using
Cochrane Collaboration's software (Review Manager
[RevMan] Version 5.0 for Windows. Copenhagen: The
Nordic Cochrane Center). Chi-square and Higgins I2 tests
were used to assess heterogeneity. Where more than 10
studies were available, we assessed publication bias using
a funnel plot or Egger's regression test [14,15].
Results
Study description
Our searches identified 377 potentially relevant studies,
of which 5 met our inclusion criteria (Figure 1). The key
data from all included RCTs are listed in Table 1[16-20].
All of the RCTs originated from China. Four adopted a
two-arm parallel group design [16,18-20], and one
adopted a three-arm parallel group design [17]. In all
RCTs, the treatment was based on the principles of tradi-
tional Chinese medicine (TCM) as the rationale for
selecting the acupuncture point. Selected acupuncture
points from all trials and other information related to
treatments are listed in sufficient detail in Table 2. Most
of the included studies used response rate for each inter-
vention, and outcomes were typically divided into four
categories, including (1) recovery, (2) marked improve-
ment, (3) improvement, and (4) no change. These were
based on the both physician's assessment and the results
of endoscopy in three trials [18-20], while the other two
studies employed physician assessment [16,17]. The set-
ting was described in one trial [19], while the others did
not report such details [16-18,20].
Risk of bias
All of the included RCTs had high risk of bias. Of the five
included RCTs, four did not describe the sequence gener-
ation. One RCT employed the methods of sequence gen-
eration incorrectly [19]. None of the studies described
any attempt to blind assessors. All of the RCTs reported
incomplete outcome measures and allocation conceal-
ment. Adverse events were mentioned only in one RCT
[20].
Description of individual studies
Wen [16] conducted an RCT assessing the effectiveness
of moxibustion on symptoms of UC patients. Sixty-nine
patients were divided randomly into two parallel groups:
moxibustion (n = 39) and sulfasalazine (n = 30). At the
end of the treatment period, 89.8% of patients from theLee et al. BMC Gastroenterology 2010, 10:36
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experimental group had improved, while the correspond-
ing figure in the control group was 66.8% (P < 0.05).
Wu and co-workers [17] tested the effects of moxibus-
tion in 151 patients who were divided randomly into a
three parallel groups: moxibustion group I (details of
composition are listed in Table 2, n = 65), moxibustion
group II (details of composition are listed in Table 2, n =
56), and a sulfasalazine group (n = 30). The response rate
was 92.3% in moxibustion group I, 89.3% in moxibustion
group II, and 66.7% in the sulfasalazine group.
Ding and co-workers [18] conducted an RCT to test the
therapeutic effect of ginger moxibustion on Yang defi-
ciency of the spleen and kidney in patients with UC.
Sixty-one patients were randomly divided into two
Table 1: Summary of randomized clinical studies of moxibustion for ulcerative colitis with parallel design
First author (Year) 
[ref]
Sample size (M/F)
Duration of disease
Age (range)
Setting*
(author's affiliation)
Experimental 
intervention
Control intervention Response rate§
(basis of assessment)
Wen
(2003) [16]
69 (35/34)
(A) 6 mon-14 yrs
(B) 4 mon-16 yrs
23-69 yrs
n.r.
(TCM hospital)
(A) Moxa [once daily 
for 12 days (1 session), 
3 day intervals 
between courses, total 
6 sessions n = 39]
Indirect
(B) Sulfasalazine (SASP, 
oral, 1 g × 4/d, for 3 
months, n = 30)
A(89.8%, 35/39); 
B(66.8%, 20/30)
P < 0.05
(Physician's 
assessment)
Wu
(1999) [17]
151 (n.r.)
(A) 6 mon-18 yrs
(B) 4 mon-16 yrs
(C) 4 mon-17 yrs
25-70 yrs
n.r.
(TCM institute and 
Western hospital)
(A) Moxa I [once daily 
for 12 days (1 session), 
3 day intervals 
between courses, total 
6 sessions n = 65]
(B) Moxa II(same as A, n 
= 56)
Indirect
(C) Sulfasalazine (SASP 
only, oral, early: 1 g × 4/
d, firmly: 0.5 g × 4/d, for 
3 months, n = 30)
A(92.3%, 60/65); 
B(89.3%, 50/56);
C (66.7%, 20/30)
A, C: P < 0.01;
B, C: P < 0.05
(Physician's 
assessment)
Ding
(2009) [18]
61 (32/29)
(A) 3 mon-20 yrs
(B) 3 mon-17 yrs
19-71 yrs
n.r.
(Western hospital)
(A) Moxa [20 min, once 
daily for 2 months, n = 
30]
Indirect (ginger)
(B) Sulphasalazine 
(oral, 1 g × 4/d, for 1 
month, n = 31)
A(100%, 30/30); 
B(90.3%, 28/31)
P < 0.05
(Physician's 
assessment, 
endoscopy)
Wang
(2006) [19]
60 (28/32)
(A) 0.5-12 yrs
(B) 0.6-13 yrs
27-54 yrs
TCM hospital and 
private clinics
(TCM hospital and 
private clinics)
(A) Moxa [once daily 
for 12 days (1 session), 
3 day intervals 
between courses, total 
3 sessions n = 30]
Indirect
(B) Sulphasalazine (1.0 
g × 4/d) and 
Metronidazole (0.2 g × 
3/d), oral, [once daily 
for 10 days (1 session), 
3 day intervals 
between courses, total 
3 sessions n = 30]
A(86.7%, 26/30); 
B(66.7%, 20/30)
P < 0.05
(Physician's 
assessment, 
endoscopy)
Zhou (2003) [20] 66 (31/35)
2-8 yrs
19-50 yrs
n.r.
(TCM hospital)
(A) Moxa [once daily 
for 10 days (1 session), 
3 day intervals 
between courses, total 
3 sessions n = 34]
Indirect (ginger)
(B) Sulfasalazine (SASP, 
oral, 0.5 g × 4/d), for 30 
days, n = 32] plus 
Prednisone [(oral, 10 
mg × 4/d but reduce to 
10 mg/d if getting a 
more stable state)
A(97.1%, 33/34); 
B(71.9%, 23/32)
P < 0.05
(Physician's 
assessment, 
endoscopy)
Sulfasalazine: Anti-inflammatory, Metronidazole: Antibiotic, Prednisone: A synthetic anti-inflammatory glucocorticoid derived from 
cortisone,
SASP: salicylazosulfapyridine, ACTH: Adreno-Cortico Tropin Hormone, ACH: Adreno-Cortical Hormone
*The most of trials didn't describe the place of remision or neing treaed for active disease in the text. Alternatevely, we report the affiliation 
of the authors in the brackets.
§Trial divided into three or four categories, including (1) recovery, (2) marked improvement, (3) improvement, and (4) no change in terms of 
symptom and results of endoscopy.Lee et al. BMC Gastroenterology 2010, 10:36
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Table 2: Summary of treatment points and other information related to treatment
First author (Year) [ref], 
Country
Treatment points Rationales Adverse events
Wen
(2003)[16]
China
Fixed points: (10 points: A and 
B were alternately treated)
A) CV12, CV6, ST36
B) BL25, ST25, ST37
Possible additional 
points(individualized):
Spleen and stomach 
deficiency-BL20; Damp heat 
accumulation-CV9;
Liver stagnation and spleen 
deficiency-BL18, BL20;
Spleen and kidney yang 
deficiency-BL23, CV4
TCM theory and
modern scientific evidence
n.r.
Wu
(1999)[17]
China
Fixed points: (10 points: A and 
B were alternately treated)
A) CV12, CV6, ST36
B) BL25, ST25, ST37
Possible additional 
points(individualized):
Spleen and stomach 
deficiency-BL20; Damp heat 
accumulation-CV9;
Liver stagnation and spleen 
deficiency-BL18, BL20;
Spleen and kidney yang 
deficiency-CV4; Constipation-
KI15; Pyemia(severe)-SP1
Medicinal cake consist of:
Moxibustion Group I-Aconiti 
Lateralis Radix Preparata, 
Cinnamomi Cortex Spissus, 
Salviae Miltiorrhizae Radix, 
Carthami Flos, Aucklandiae 
Radix, Coptidis Rhizoma, etc.
Moxibustion Group II-Santali 
Albi Lignum, Syzygii Flos, 
Bomeolum, Zanthoxyli 
Fructus, etc.
TCM theory and
clinical experiences
n.r.
Ding
(2009) [18]
China
Fixed points: (8 points)
BL13, BL20, BL23, BL25
TCM theory n.r.
Wang
(2006)[19]
China
Fixed points: (1 point)
CV8
TCM theory, previous studies
and anatomical features
n.r.
Zhou
(2003)[20]
China
Fixed points: (12 points: A and 
B were alternately treated)
A) CV12, ST25, ST36, BL20, 
BL26
B) CV12, ST25, ST36, BL23, GV4
A), B): alternately every day
TCM theory None
TCM: Traditional Chinese Medicine; n.r.: not reportedLee et al. BMC Gastroenterology 2010, 10:36
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groups. Thirty patients were given ginger moxibustion,
while in the control group 31 patients were administered
sulfasalazine. The effectiveness rate was 100%, and the
curative effect was 90.0% in the experimental group.
These rates were significantly better than in the control
group (90.3% and 35.5%, respectively; P < 0.01).
Wang and co-workers [19] conducted an RCT to test
the therapeutic effect of moxibustion at Shenque (CV8)
on UC. Sixty patients were randomly divided into two
parallel groups: moxibustion (n = 30) and sulfasalazine
plus metronidazole (n = 30). The total response rate was
86.7% in the moxibustion group and 66.7% in the control
group.
Zhou [20] randomized 60 patients into two parallel
groups: moxibustion (n = 34) and prednisone plus sul-
fasalazine (n = 32). Response rates were measured by
symptoms, fiber colonoscopy, endoscopy, and pathologi-
cal examination. The total effective rate was 97.1% in the
moxibustion group and 71.9% in the control group (P <
0.05). No adverse event was reported.
Meta-analysis
The meta-analysis of the five RCTs [16-20] suggested
favorable effects of moxibustion on the RR compared
with conventional drug therapy (n = 407; RR = 1.24, 95%
CI = 1.11 to 1.38; P < 0.0001; heterogeneity: I2 = 16%, Fig-
ure 2). A subgroup analysis [16-18] also demonstrated
beneficial effects of moxibustion compared to sulfasala-
zine alone (n = 281; RR = 1.23, 95% CI = 1.04 to 1.46; P =
0.01; heterogeneity: I2 = 39%). A further analysis [19,20]
showed favorable effects of moxibustion compared to sul-
fasalazine plus metronidazole or prednisone (n = 126; RR
= 1.33, 95% CI = 1.11 to 1.59; P = 0.002; heterogeneity: I2
= 0%).
We could not assess publication bias because of the low
number of studies [14,15].
Discussion
Few RCTs have tested the effects of moxibustion for UC,
and none of the existing trials were methodologically rig-
orous. Our meta-analysis suggests that moxibustion is
effective; however, the number of trials, their quality and
the total sample size are too low to allow firm conclu-
sions.
Cochrane criteria were used to quantify the likelihood
of bias inherent in the studies based on the description of
sequence generation, incomplete outcome measures,
blinding and allocation concealment. All included RCTs
had high risk of bias. Low-quality trials (high risk of
biased trials) are more likely to overestimate the effect
size [21]. None of the RCTs described attempts to blind
patient or assessors, dropouts and withdrawals, or alloca-
tion concealment. In addition, all RCT s failed to report
details regarding ethical approval. Thus, the reliability of
the evidence presented here is clearly limited.
It has been repeatedly noted that trials originating from
China are rarely, if ever, negative [22]. All of the included
RCTs originated from China. The absence of negative
results is a largely unexplained phenomenon. Whatever
Figure 1 Flow chart of trial selection process. RCT: randomized clin-
ical trial.
Figure 2 Forest plot of moxibustion for ulcerative colitis com-
pared to conventional drug. Moxa: moxibustion.Lee et al. BMC Gastroenterology 2010, 10:36
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the causes, it does not increase our confidence in these
studies.
In the absence of reliable data from controlled clinical
trials, other types of evidence might be helpful. The
results of all of the uncontrolled trials or case reports
implied that acupuncture improves symptoms of UC.
Unfortunately, such data are highly susceptible to bias;
hence, they provide little useful information on the spe-
cific effects of moxibustion as a therapeutic intervention
for UC.
By considering moxibustion as a type of therapeutic
intervention by stimulating acupuncture points, we could
include three other RCTs (Additional file 1). Three RCTs
tested acupuncture plus moxibustion versus conventional
medicines [23-25]. Two RCTs compared acupuncture
plus moxibustion with sulfasalazine [23,24]. One RCT
reported favorable effects of acupuncture plus moxibus-
tion compared to drug therapy [23], while the two other
RCTs failed to do so [24,25]. The pooling of these three
RCTs failed to showed favorable effects of moxibustion
plus acupuncture for UC compared to drug therapy (n =
273; RR = 1.15, 95% CIs = 0.91 to 1.46; P = 0.24), although
marked heterogeneity was observed in this model (χ2 =
15.27; P = 0.0005; I2 = 87%; Additional file 2).
Assuming that moxibustion is a beneficial treatment for
UC, its mechanisms may be of interest. These may
include improvement of immune function or effects on
intestinal mucosal morphology and expression of GH and
IGF-I [10,26]. None of these theories, however, are cur-
rently more than speculation.
Limitations of our systematic review (and indeed sys-
tematic reviews in general) pertain to the potential
incompleteness of the evidence reviewed. We aimed to
identify all studies on the subject. The distorting effects
of publication bias and location bias on systematic
reviews and meta-analysis are well documented [27-30].
In the present review, there were no restrictions on the
review publication language, and a large number of dif-
ferent databases were searched. We are, therefore, confi-
dent that our search strategy located all relevant data on
the subject. However, a degree of uncertainty remains.
Further limitations include the paucity and the often sub-
optimal quality of the primary data. Additionally, all
included RCTs that reported positive results came from
China, one of the countries that produces virtually no
negative results [31], a fact that casts some doubt on the
validity of such data. All of the included studies were con-
ducted in Asia, therefore making the conclusions limited
to Asian populations. For other populations, independent
replications are required. None of the RCTs included in
our review were successful in minimizing bias. Collec-
tively, these facts seriously limit the conclusiveness of our
systematic review.
Future studies in UC treatment with moxibustion
should emphasize adequate methods to permit RCTs and
the use of pilot trials to help prepare appropriate RCTs.
Long-term studies are also needed to determine the lon-
gevity of treatment effects. Moreover, a cost-analysis
should be considered.
Conclusion
The evidence that moxibustion is an effective treatment
f o r  U C  i s  i n c o n c l u s i v e .  E v e n  t h o u g h  t h e  t r i a l  d a t a  a r e
unanimously positive, too many important caveats exist
to draw firm conclusions.
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